Abstract
Background
UMOD is exclusively produced by renal epithelial cells. Recent genome-wide association studies (GWAS) suggested that common variants in UMOD gene are closely connected with the risk of CKD. However, a comprehensive and objective report on the current status of UMOD research is lacking. Therefore, we aim to conduct a bibliometric analysis to quantify and identify the status quo and trending issues of UMOD research in the past.
Methods
We collected data from the Web of Science Core Collection database and used the Online Analysis Platform of Literature Metrology, the Online Analysis Platform of Literature Metrology and Microsoft Excel 2019 to perform bibliometricanalysis and visualization.
Results
Based on the data from the WoSCC database from 1985 to 2022, a total of 353 UMOD articles were published in 193 academic journals by 2346 authors from 50 different countries/regions and 396 institutions. The United States published the most papers. Professor Devuyst O from University of Zurich not only published the greatest number of UMOD-related papers but also is among the top 10 co-cited authors. KIDNEY INTERNATIONAL published the most necroptosis studies, and it was also the most cited journal. High-frequency keywords mainly included ‘chronic kidney disease’, ‘Tamm Horsfall protein’ and ‘mutation’.
Conclusions
The number of UMOD-related articles has steadily increased over the past decades Current UMOD studies focused on Biological relevance of the UMOD to kidney function and potential applications in the risk of CKD mechanisms, these might provide ideas for further research in the UMOD field.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Tamm–Horsfall protein is the most abundant urinary protein in physiological conditions, and was discovered by Igor Tamm and Frank Horsfall in 1950 [1]. Muchmore and Decker isolated a glycoprotein with immunomodulatory activity, which was named uromodulin (UMOD), from the urine of pregnant women In 1985 [2]. However, in 1987, it is demonstrated that Tamm–Horsfall protein and UMOD were, in fact, the same protein product [3]. UMOD is mostly (90%) produced by epithelial cells lining the thick ascending limb of Henle’s loop and to a lesser extent (10%) by epithelial cells of the early part of the distal convoluted tubule [4]. In the past two decades, Interest in UMOD was boosted by genetic studies that reported involvement of the UMOD gene, which encodes UMOD, in a spectrum of rare and common kidney diseases. This protein might regulate salt transport, protect against urinary tract infection and kidney stones, and have roles in kidney injury and innate immunity [5]. A recent meta-GWAS showed that UMOD is among the most outstanding loci associated with CKD in the general population, and it has a large effect on eGFR and CKD risk, a condition that affects up to 10% of the population worldwide [6]. In recent years, a positive correlation between serum uromodulin levels and kidney function was confirmed by several studies on populations with kidney disease of different etiology [7]. Moreover, serum UMOD was shown to be more sensitive than conventional markers (serum creatinine, urea, and cystatin C) reflecting glomerular filtration to detect early stage CKD [8]. A lately prospective cohort study enrolled 1538 hospitalized patients in a multicenter reminded that higher urinary uromodulin levels were associated with smaller eGFR declines and decreased incidence of the composite kidney outcome [5]. These findings raise the possibility that modulating circulating UMOD levels could have therapeutic potential on CKD. Therefore, we undertook a bibliometric analysis and visual analysis to explore the hotspots and frontier directions to gain further insight into the pathways connecting UMOD and CKD, ho** to provide researchers with some useful guidance.
Materials and methods
Data collection
The Web of Science Core Collection (WoSCC) database is widely used in bibliometrics, which contains Science Citation Index Expanded (SCIE),Social Science Citation Index (SSCI), and Emerging Sources Citation Index (ESCI) [9, 10]. The data search was conducted on 5 July 2022 through the WoSCC database from 1985 to 2022. The search formula was [TS = (Tamm–Horsfall protein) OR TS = (UMOD) OR TS = (umod) OR TS = (thp)] AND [TS = (chronic kidney disease) OR TS = (chronic renal disease)]. Search results were downloaded as “Full Record and Cited References”.
Data analysis
Cite Space 6.1.R2, a bibliometric and visual analysis tool that excels at detecting cooperation, key points, internal structure, potential trends, and dynamics in a scientist field [11]. The Online Analysis Platform of Literature Metrology and Microsoft Excel 2019 were used to perform bibliometric analysis and visualization. The retrieved data was collected within 1 day to avoid any potential deviation due to the daily updating of the database. Total of 353 papers were obtained. Bibliographic information was collected, including the year of publication, authorship, publishing journals, institution, country of origin and keywords. Furthermore, the impact factor (IF) and Journal citation reports (JCR) division of journals and the H-index of scholars were obtained from the Web of Science on January 5, 2023.
Results
Overview of publications on UMOD
Figure 1 shows the annual number of UMOD-related publications which continually increased over time. The annual growth rate is 8.67%. More scholars started to research in this field especially after the year of 2010. The number of UMOD-related articles has steadily increased over the past decade. A Johns Hopkins University research team conducted genome-wide association studies to identify susceptibility loci for chronic kidney disease, which found that rare mutations in UMOD may influence renal function and cause mendelian forms of kidney disease [12], which caused widely attention in this field, and it was cited by 432 times (Fig. 2). This high index article may contribute to the continually increased researches in this field since the year of 2010.
Distribution characteristics of the literature
This study design contains articles (n = 281), review articles (n = 58), meeting abstract (n = 7), editorial materials (n = 6), and proceeding paper (n = 1) (Table 1). The most cited article was published in 2009 with the citation being 432 [12]. M Lucrecia Alvarez’s research published in 2012 was cited 369 times [13] (Fig. 2). The oldest paper on the list was published in 1997 by B Settergren et al. and was cited 23 times [14]. The most recent paper has not been cited and was published in 2022 by Laura et al. [15]. Moreover, 20 documents are cited over 100 times.
Distribution characteristics of countries/regions and institutions
A total of 353 UMOD-related papers were from 50 different countries/regions and 396 institutions. The United States published the most papers (n = 130), followed by Germany (n = 69) and Italy (n = 36) (Table 2). The United States had the highest centrality (centrality = 0.42), which means the United States may be a “bridge” node inumod studies (Fig. 3). The collaboration of countries/regions involved is shown in Fig. 4. To date, the United States has been the largest contributor to UMOD researches.
Univ Calif San Diego is the most productive institution (n = 21), followed by Univ Calif San Francisco (n = 17) and Charles Univ Prague (n = 13). However, its centrality is relatively low (n = 86, centrality = 0.07). By contrast, Harvard Medical School (n = 70, centrality = 0.14), Ghent University (n = 77, centrality = 0.12), and St. Jude Children’s Research Hospital (n = 55, centrality = 0.10) had a high centrality (Fig. 5). In addition, Brigham and Womens Hosp (centrality = 0.10), Harvard Univ (centrality = 0.08), and INSERM (centrality = 0.8) had a high centrality (Table 3).
Distribution of articles by authors and co-cited authors
A total of 2346 authors were involved in the UMOD researches, among them, 91 authors published at least ten papers per person (Fig. 6; Table 4). Olivier Devuyst from the University of Zurich in Switzerland published the highest number of the UMOD-related papers (n = 19) followed by Anthony J Bleyer and Michael G Shlipak (Table 4). There were 9 colors in Fig. 6, representing 9 clusters among authors. Active collaborations usually exist in the same cluster, such as JERUMS G and DELLES C.
Co-cited authors are the authors who were cited in one article [16]. Among 718 co-cited authors, 10 had over 10 co-citations (Table 5). Kottgen A is the highest frequency co-cited author (n = 21), followed by Rampoldi L (n = 17) and Hart TC (n = 13). However, LIU Y had the highest centrality (centrality = 0.19), followed by Hoyer JR (centrality = 0.14) and Kumar S (centrality = 0.13) (Table 5).
Journals and co-cited academic journals
A total of 193 academic journals published articles in the UMOD field. The top 10 journals published 101 papers in total, accounting for 28.61% of all publications of UMOD field (Table 6). Kidney International had the greatest number of publications (n = 19), followed by Nephrology Dialysis Transplantation (n = 17) and PLOS One (n = 12) (Table 6). Among 2123 co-cited sources, 31 journals had more than 100 citations, among which, SCIENCE (n = 170), NATURE (n = 164), LANCET (n = 160), and KIDNEY INT (n = 1149) had the greatest number of citations, followed by J AM SOC NEPHROL (n = 1135) (Table 7).
Co-cited references and reference burst
Table 8 showed the top 10 of the 12,488 co-cited references. Among them, 8 of the top 10 were research articles, 2 were reviews. The top 1 of the co-cited reference is an article published in J Med Genet by T C Hart et al. in 2022 (n = 90). Two articles published by Luca Rampoldi from San Raffaele Scientific Institute have been cited by 59 and 56 times, respectively, which ranked to the fourth and fifth of the top 10 co-cited references [17, 18]. Three articles published by Anna Köttgen from Johns Hopkins University have been cited by 74, 51 and 45 times, respectively, which ranked to the second, seventh and tenth of the top 10 co-cited references (Table 8) [12, 19, 20].Those two authors had made great contributions to the research of UMOD, which is the foundation of the knowledge related to the UMOD research.
The references timeline view could visualize the evolution of research hotspots over time. The terms with the highest frequency in each cluster were tagged as cluster labels. As shown in Fig. 7, cluster #3(fixed particle) and #8(familial juvenile hyperuricemic nephropathy) started earlier; while cluster #0 (serum UMOD), #4 (ADTKD) and #5(urine biomarkers hiv ckd) are still ongoing, which could be considered as the frontier.
References with citation bursts are those that have been cited with a relatively higher frequencies over a period. A total of 70 references were detected as citation bursts, and we listed the top 20 in Fig. 8. The strongest burstness (strength = 13.01) occurred in a paper entitled “The rediscovery of UMOD (Tamm–Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease”, published in Kidney Int by Rampoldi L et al. in 2011, with citation burstness from 2012 to 2016 [18]. Notably, four references were still in burstness [5, 8, 11, 21].
Keyword analysis of trending research topic
A total of 1251 keywords were extracted, among which 48 keywords appeared at least ten times. The top 10 keywords in terms of frequency and centrality for publications in UMOD field are listed in Table 9. The most common keywords were ‘chronic kidney disease’, ‘Tamm Horsfall protein’ and ‘mutation’. Regarding the centrality index, ‘Tamm Horsfall protein’ (0.27) was the most important keyword related to UMOD, followed by ‘chronic kidney disease’ (0.25), and ‘cardiovascular disease’ (0.19). The timeline view (Fig. 9) presented the top 3 high-frequency keywords in each cluster over time. The cluster #2, #5 and #7 are still ongoing. Among them, cluster #0 (eGFR) is the biggest cluster, followed by cluster #1 (familial juvenile hyperuricemic nephropathy), cluster #2 (expression), and cluster #3 (diabetic nephropathy).
Keyword bursts are those that were cited significantly frequently over a period. As shown in Fig. 10, ‘mortality’ had the strongest bursts (strength = 5.7), followed by ‘injury ‘(strength = 5.05) and ‘Tamm Horsfall protein’ (strength = 8.06). Notably, ‘mortality’, ‘injury’, ‘urinary uromodulin’, ‘serum uromodulin’, and ‘diagnosis’ were still in burstness until 2022.
Discussion
General information
Based on the data from the WoSCC database from 1985 to 2022, a total of 353 UMOD articles were published in 193 academic journals by 2346 authors from 50 different countries/regions and 396 institutions.
The increasing trend of publications indicated that UMOD relationship with CKD is attracting mounting attention and interest. A research from the Johns Hopkins University team conducted a genome-wide association study to identify susceptibility loci for chronic kidney disease, which found that rare mutations in UMOD may influence renal function [12], since then, the UMOD research has grown rapidly.
In country/region analysis, the number of publications and betweenness centrality are two vital indicators. High centrality (≥ 0.10) nodes imply the “bridge” effects of those countries/regions in the global cooperation network [11, 22,23,25,26,27]. Among the top 10 co-cited references, eight articles mainly reported the involvement of the UMOD gene in the aspectrum of rare and common kidney diseases. Two reviews summarized the UMOD investigations of biological function related to CKD. As for reference burst analysis (Fig. 8), four references are still in burst and worth our attention: one observation study reported that plasma UMOD serves as a robust biomarker for kidney function and uniquely allows the identification of early stages of CKD [28]. One of the prospective cohort studies reported that serum UMOD may be a useful marker of cardiovascular and renal health [21]. The other concluded that serum UMOD is a novel sensitive kidney-specific biomarker linked to the structural integrity of the distal nephron and to the renal function [29].One reviews summarized biochemical, physiological, genetic and pathological insights into the roles of UMOD [5].
The hotspots and trending
It’s critical to researchers to keep abreast of the trending in the research field in such an era of information explosion. Bibliometrics provides a method in which keyword co-occurrence can reflect the hotpots of an academic area [26, 32].In this study, we tried to objectively evaluate the hotpots and frontiers of UMOD research through the analysis of keyword co-occurrence (Table 9), keyword timeline (Fig. 9), keyword burst (Fig. 10), reference timeline (Fig. 7), and reference burst (Fig. 8). We summarized the aspects as follows.
Biological relevance of the UMOD to kidney function
More conclusive evidence was obtained in vivo through the characterization of UMOD gene knockout mice. The UMOD polymers promotes clearance of the pathogens by forming a 3D meshwork acting as a “fishing net” that can trap microorganisms to eliminate them by micturition [33, 34], which was later confirmed in vivo [35].The protein in the urine protect are against kidney stone formation [36]. Consistent results were observed in several case–control studies showing decreased urinary UMOD levels in kidney stone formers [37,38,39]. UMOD was shown in vitro to decrease caveolin-mediated endocytosis of TRPV5 and TRPV6 (two channels responsible for transcellular Ca2+ reabsorption), which increased surface abundance of both channels and thus increased calcium reabsorption [40, 41]. UMOD plays an important role in sodium homeostasis in the TAL and DCT, thus regulating blood pressure and urinary concentrating ability [42]. In vivo studies ischemia–reperfusion injury models of acute kidney injury (AKI) showed increased inflammation and necrosis in kidneys of UMOD gene knockout mice, suggesting a protective role of UMOD in kidney [43]. All these processes are relevant when considering the onset of CKD, tubulointerstitial injury, and the complications arising from kidney failure.
A transgenic mouse model overexpressing wild-type UMOD, displayed a dose-dependent increase in systolic blood pressure, with salt-sensitive hypertension. Aging kidneys from the UMOD transgenic mice showed focal lesions (e.g., tubular casts, cysts) and increased expression of kidney damage markers (e.g., lipocalin-2, Kim-1) and chemokines. Genetically driven higher production of uromodulin becomes deleterious over time, promoting the onset of CKD [44].In some genome-wide association studies(GWAS), the UMOD alleles associated with higher uromodulin expression/levels are associated with increased risk of CKD, hypertension, and hyperuricemia, whereas they are protective against kidney stones [38, 45],indicating it’s importance for a set of common diseases.
Rare mutations in UMOD
‘Familial juvenile hyperuricemic nephropathy’ (FJHN) was mentioned in Figs. 7 and , ‘Autosomal dominant tubulointerstitial kidney disease’(ADTKD) in Fig. 7. These diseases including ‘familial juvenile hyperuricemic nephropathy (FJHN)’, ‘medullary cystic kidney disease (MCKD) type 2’, ‘uromodulin-associated kidney disease (UAKD)’, UMOD-related diseases, and ‘MCKD type 1’, suggested the adoption of new terminology using a single name ‘autosomal dominant tubulointerstitial kidney disease’ (ADTKD) by KDIGO [46]. Rare dominant mutations in UMOD represent the most frequent cause of ADTKD (ADTKD–UMOD).
ADTKD is an increasingly recognized cause of end-stage kidney disease, characterized by tubular damage and interstitial fibrosis of the kidney in the absence of glomerular lesions. Affected individuals present with urinary concentrating defects, progressive CKD, normal-to-mild proteinuria, and normal-sized kidneys, often has a positive family history [47, 48]. Studies of mouse models carrying uromodulin mutations confirmed that intracellular accumulation of mutant uromodulin may lead to ER stress, induction of the unfolded protein response, and subsequent tubular damage and interstitial fibrosis—substantiating the gain of toxic function mechanism in ADTKD–UMOD [45]. In addition, the defective biogenesis and intracellular uromodulin transport affect the Na–K–2Cl cotransporter resulting in defective urinary concentration and mild volume depletion, secondarily increasing proximal reabsorption of uric acid, leading to hyperuricemia [18].
Potential applications of UMOD in CKD
According to our results (Figs. 7, 9, 10), ‘biomarker’ is all mentioned. ‘mortality’, ‘injury’, ‘urinary uromodulin’, ‘serum uromodulin’, and ‘diagnosis’ were in burstness until 2022. In both SKIPOGH and CoLaus cohorts studies, positive associations were found between uromodulin and urinary sodium, chloride, and potassium excretion and osmolality [49]. In SKIPOGH, 24-h uromodulin excretion was positively associated with kidney length and volume and with creatinine excretion and urine volume. However, it was negatively associated with age and diabetes. The associations of UMOD excretion with markers of tubular functions and kidney dimensions suggest that it may reflect the distal tubular transport activity (e.g., reabsorption of NaCl and/or divalent cations) in the general population. In CoLaus, the data substantiate the measurement of urinary UMOD levels as a useful surrogate marker for nephron mass. As such, higher UMOD levels may indicate a higher functional reserve of the kidney with a lower risk of acute kidney injury (AKI) [38, 45]. This situation should not be confused with the results of the GWAS studies indicating that the risk of variants of the UMOD locus, which drive higher production of uromodulin reflected by higher levels in urine and blood, are consistently associated with an increased risk of CKD) [45]. Taken together, these studies validated urinary uromodulin as a biomarker for tubular mass and tubular function in the general population as well as in the disease subgroups.
The association of UMOD with rare disorders and more common conditions, as well as the availability of validated ELISA methods for measuring urinary and serum uromodulin levels support the use of uromodulin as a biomarker of tubular function in healthy individuals and in patients with kidney disease. Early studies based on radioimmunoassays found reduced uromodulin excretion in patients with tubular damage or autosomal dominant polycystic kidney disease (ADPKD) [5]. Studies based on mass spectrometry or ELISA identified uromodulin as a potential biomarker in Fabry nephropathy, active lupus nephritis with tubulointerstitial inflammation and in ADPKD [50,51,52]. Discovering of UMOD will drive multi-level studies substantiating cellular mechanisms and possible drug targets.
Strength and limitations
Overall, this is the first bibliometric study to systematically analyze the relationship between UMOD and CKD. Compared to traditional reviews, the bibliometric analysis provides this novel and objective insight into the evolving research foci and trends [10]. Meanwhile, we used various bibliometric software to perform an analysis, which could provide richer results in multiple dimensions [53].This study will inform the scholars of the importance of UMOD, and serve as a comprehensive and objective guide for the future development of the UMOD research field. Inevitably, this study has some limitations. First, we exclusively retrieved the articles published in English from the WoSCC database, thus omitting articles that are not in WoSCC or not in English. Nevertheless, we are certain that the WoSCC provides greater transparency with regard to the coverage than other resources. Second, bibliometric methods also introduce inherent bias in our analysis, which based on natural language processing. Third, compared with older articles, recent articles did not have a tendency to accrue more citations. This may lead to several high-quality articles being excluded from our analysis.
Conclusions and perspectives
In the past two decades, the scientific interest in UMOD has grown significantly with active cooperation worldwide. United States might maintain the dominant position in UMOD research. Olivier Devuyst published the highest number of UMOD-related papers. The present studies suggested that UMOD might regulate salt transport, protect against urinary tract infection and kidney stones, and have roles in kidney injury and innate immunity. UMOD has been recognized as the largest effect on eGFR and CKD incidence and progression. Furthermore, the urinary and serum level of UMOD were shown to have a prognostic value for kidney function decline and the incidence of CKD, AKI, and ESRD. In addition, UMOD was also shown to be an effective biomarker for tubular function and nephron mass, possibly an alternative to current markers that are based on glomerular function. The molecular mechanisms linking UMOD expression and CKD risk are still unclear. The pathways through which UMOD regulates the function of ion transporters need to be further dissected. All these represent areas of great interest for future research on this multifaceted protein. It is still unknown whether there are differences in the post translational modifications of urinary and serum UMOD other than polymerization that may be associated with different biological functions.
Data availability
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.
References
Tamm I, Horsfall FL Jr (1950) Characterization and separation of an inhibitor of viral hemagglutination present in urine. Proc Soc Exp Biol Med 74(1):106–108
Muchmore AV, Decker JM (1985) Uromodulin: a unique 85-kilodalton immunosuppressive glycoprotein isolated from urine of pregnant women. Science 229(4712):479–481
Pennica D, Kohr WJ, Kuang WJ et al (1987) Identification of human uromodulin as the Tamm-Horsfall urinary glycoprotein. Science 236(4797):83–88
Tokonami N, Takata T, Beyeler J et al (2018) Uromodulin is expressed in the distal convoluted tubule, where it is critical for regulation of the sodium chloride cotransporter NCC. Kidney Int 94(4):701–715
Devuyst O, Olinger E, Rampoldi L (2017) Uromodulin: from physiology to rare and complex kidney disorders. Nat Rev Nephrol 13(9):525–544
Wuttke M, Li Y, Li M et al (2019) A catalog of genetic loci associated with kidney function from analyses of a million individuals. Nat Genet 51(6):957–972
Fedak D, Kuźniewski M, Fugiel A et al (2016) Serum uromodulin concentrations correlate with glomerular filtration rate in patients with chronic kidney disease. Pol Arch Med Wewn 126(12):995–1004
Puthumana J, Thiessen-Philbrook H, Xu L et al (2021) Biomarkers of inflammation and repair in kidney disease progression. J Clin Invest 131(3):e139927
Yan WT, Lu S, Yang YD et al (2021) Research trends, hot spots and prospects for necroptosis in the field of neuroscience. Neural Regen Res 16(8):1628–1637
Zhang J, Song L, Xu L et al (2021) Knowledge domain and emerging trends in ferroptosis research: a bibliometric and knowledge-map analysis. Front Oncol 11:686726
Chen C (2004) Searching for intellectual turning points: progressive knowledge domain visualization. Proc Natl Acad Sci U S A 101(Suppl 1):5303–5310
Köttgen A, Glazer NL, Dehghan A et al (2009) Multiple loci associated with indices of renal function and chronic kidney disease. Nat Genet 41(6):712–717
Alvarez ML, Khosroheidari M, Kanchi Ravi R, DiStefano JK (2012) Comparison of protein, microRNA, and mRNA yields using different methods of urinary exosome isolation for the discovery of kidney disease biomarkers. Kidney Int 82(9):1024–1032
Settergren B, Ahlm C, Alexeyev O, Billheden J, Stegmayr B (1997) Pathogenetic and clinical aspects of the renal involvement in hemorrhagic fever with renal syndrome. Ren Fail 19(1):1–14
Tsujikawa LM, Kharenko OA, Stotz SC et al (2022) Breaking boundaries: Pan BETi disrupt 3D chromatin structure, BD2-selective BETi are strictly epigenetic transcriptional regulators. Biomed Pharmacother 152:113230
Li C, Wu K, Wu J (2017) A bibliometric analysis of research on haze during 2000–2016. Environ Sci Pollut Res Int 24(32):24733–24742
Rampoldi L, Caridi G, Santon D et al (2003) Allelism of MCKD, FJHN and GCKD caused by impairment of uromodulin export dynamics. Hum Mol Genet 12(24):3369–3384
Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O (2011) The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 80(4):338–347
Köttgen A, Hwang SJ, Larson MG et al (2010) Uromodulin levels associate with a common UMOD variant and risk for incident CKD. J Am Soc Nephrol 21(2):337–344
Köttgen A, Pattaro C, Böger CA et al (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42(5):376–384
Delgado GE, Kleber ME, Scharnagl H, Krämer BK, März W, Scherberich JE (2017) Serum uromodulin and mortality risk in patients undergoing coronary angiography. J Am Soc Nephrol 28(7):2201–2210
Chen C, Hu Z, Liu S, Tseng H (2012) Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther 12(5):593–608
Ma L, Ma J, Teng M, Li Y (2022) Visual analysis of colorectal cancer immunotherapy: a bibliometric analysis from 2012 to 2021. Front Immunol 13:843106
Liu S, **a K, Liu X et al (2022) Bibliometric analysis of Birt-Hogg-Dubé syndrome from 2001 to 2021. Front Med (Lausanne) 9:857127
Lu C, Liu M, Shang W et al (2020) Knowledge map** of angelica sinensis (Oliv.) Diels (Danggui) research: a scientometric study. Front Pharmacol 11:294
Chen C (2017) Science map**: a systematic review of the literature. J Data Inf Sci 2(02):1–40
Chaomei C, Citespace II (2005) Detecting and visualizing emerging trends and transient patterns in scientific literature. J Am Soc Inf Sci Technol 57(3):1–4
Steubl D, Block M, Herbst V et al (2016) Plasma uromodulin correlates with kidney function and identifies early stages in chronic kidney disease patients. Medicine (Baltimore) 95(10):e3011
Scherberich JE, Gruber R, Nockher WA et al (2018) Serum uromodulin-a marker of kidney function and renal parenchymal integrity. Nephrol Dial Transplant 33(2):284–295
**ao F, Li C, Sun J, Zhang L (2017) Knowledge domain and emerging trends in organic photovoltaic technology: a scientometric review based on CiteSpace analysis. Front Chem 5:67
Wang Y, Jia Y, Li M, Jiao S, Zhao H (2021) Hotspot and frontier analysis of exercise training therapy for heart failure complicated with depression based on web of science database and big data analysis. Front Cardiovasc Med 8:665993
Chen C, Song M (2019) Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One 14(10):e0223994
Cavallone D, Malagolini N, Serafini-Cessi F (2001) Mechanism of release of urinary Tamm-Horsfall glycoprotein from the kidney GPI-anchored counterpart. Biochem Biophys Res Commun 280:110–114
Bjugn R, Flood PR (1988) Scanning electron microscopy of human urine and purified Tamm-Horsfall’s glycoprotein. Scand J Urol Nephrol 22:313–315
Garimella PS, Bartz TM, Ix JH, Chonchol M, Shlipak MG et al (2017) Urinary uromodulin and risk of urinary tract infections: the cardiovascular health study. Am J Kidney Dis 69:744–751
Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR (2007) Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Ren Physiol 293:F1935–F1943
Romero MC, Nocera S, Nesse AB (1997) Decreased Tamm-Horsfall protein in lithiasic patients. Clin Biochem 30:63–67
Glauser A, Hochreiter W, Jaeger P, Hess B (2000) Determinants of urinary excretion of Tamm-Horsfall protein in non-selected kidney stone formers and healthy subjects. Nephrol Dial Transplant 15:1580–1587
Lau WH, Leong WS, Ismail Z, Gam LH (2008) Qualification and application of an ELISA for the determination of Tamm Horsfall protein (THP) in human urine and its use for screening of kidney stone disease. Int J Biol Sci 4:215–222
Bachmann S, Mutig K, Bates J, Welker P, Geist B et al (2005) Renal effects of Tamm-Horsfall protein (uromodulin) deficiency in mice. Am J Physiol Ren Physiol 288:F559–F567
Mutig K, Kahl T, Saritas T, Godes M, Persson P et al (2011) Activation of the bumetanide-sensitive Na+, K+,2Cl− cotransporter (NKCC2) is facilitated by Tamm-Horsfall protein in a chloride-sensitive manner. J Biol Chem 286:30200–30210
Devuyst O, Bochud M, Olinger E (2022) UMOD and the architecture of kidney disease. Pflugers Arch 474(8):771–781
El-Achkar TM, Wu XR, Rauchman M, McCracken R, Kiefer S, Dagher PC (2008) Tamm-Horsfall protein protects the kidney from ischemic injury by decreasing inflammation and altering TLR4 expression. Am J Physiol Ren Physiol 295:F534–F544
Trudu M, Janas S, Lanzani C et al (2013) Common noncoding UMOD gene variants induce salt-sensitive hypertension and kidney damage by increasing uromodulin expression. Nat Med 19:1655–1660
Schaeffer C, Devuyst O, Rampoldi L (2021) Uromodulin: roles in health and disease. Annu Rev Physiol 10(83):477–501
Shamam YM, Hashmi MF (2023) Autosomal dominant tubulointerstitial kidney disease. StatPearls. StatPearls Publishing, Treasure Island (FL)
Devuyst O, Olinger E, Weber S, Eckardt KU, Kmoch S, Rampoldi L, Bleyer AJ (2019) Autosomal dominant tubulointerstitial kidney disease. Nat Rev Dis Primers 5(1):60
Eckardt KU, Alper SL, Antignac C, Bleyer AJ, Chauveau D, Dahan K, Deltas C, Hosking A, Kmoch S, Rampoldi L, Wiesener M, Wolf MT, Devuyst O, Kidney Disease: Improving Global Outcomes (2015) Autosomal dominant tubulointerstitial kidney disease: diagnosis, classification, and management—a KDIGO consensus report. Kidney Int 88(4):676–683
Pruijm M, Ponte B, Ackermann D, Paccaud F, Guessous I, Ehret G, Pechère-Bertschi A, Vogt B, Mohaupt MG, Martin PY, Youhanna SC, Nägele N, Vollenweider P, Waeber G, Burnier M, Devuyst O, Bochud M (2016) Associations of urinary uromodulin with clinical characteristics and markers of tubular function in the general population. Clin J Am Soc Nephrol 11(1):70–80
Matafora V, Cuccurullo M, Beneduci A, Petrazzuolo O, Simeone A, Anastasio P, Mignani R, Feriozzi S, Pisani A, Comotti C, Bachi A, Capasso G (2015) Early markers of Fabry disease revealed by proteomics. Mol Biosyst 11(6):1543–1551
Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY (2000) Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron 85(3):207–214
Kistler AD, Mischak H, Poster D, Dakna M, Wüthrich RP, Serra AL (2009) Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 76(1):89–96
Shen J, Shen H, Ke L, Chen J, Dang X, Liu B et al (2022) Knowledge map** of immunotherapy for hepatocellular carcinoma: a bibliometric study. Front Immunol 13:815575
Funding
This work was supported by the National Natural Science Foundation of Chinese PLA General Hospital for National Distinguished Young Scholar Science Fund(2019-JQPY-002), National Natural Science Foundation of China(NO.82204744, 82270758 and 82070741), and National Key Research and Development Project (2018YFE0126600).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
All authors declare that they have no conflict of interest
Ethical approval
No need.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Sun, G., Liu, C., Song, C. et al. Knowledge map** of UMOD of English published work from 1985 to 2022: a bibliometric analysis. Int Urol Nephrol 56, 249–261 (2024). https://doi.org/10.1007/s11255-023-03664-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-023-03664-4